Citadel Advisors
KURA icon

Citadel Advisors’s Kura Oncology KURA Stock Holding History

Citadel Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$759K Sell
69,200
-15,100
-18% -$142K ﹤0.01% 8877
2026
Q1 		$685K Sell
84,300
-66,000
-44% -$567K ﹤0.01% 8535
2025
Q4 		$1.56M Buy
150,300
+109,400
+267% +$1.15M ﹤0.01% 6417
2025
Q3 		$362K Buy
40,900
+21,500
+111% +$153K ﹤0.01% 9915
2025
Q2 		$112K Sell
19,400
-14,200
-42% -$87K ﹤0.01% 11244
2025
Q1 		$222K Buy
33,600
+19,900
+145% +$155K ﹤0.01% 10253
2024
Q4 		$119K Buy
13,700
+4,000
+41% +$57.6K ﹤0.01% 11203
2024
Q3 		$190K Sell
9,700
-12,400
-56% -$251K ﹤0.01% 10234
2024
Q2 		$455K Buy
22,100
+12,300
+126% +$253K ﹤0.01% 8247
2024
Q1 		$209K Buy
9,800
+1,600
+20% +$31.1K ﹤0.01% 10234
2023
Q4 		$118K Sell
8,200
-2,100
-20% -$20.6K ﹤0.01% 10726
2023
Q3 		$93.9K Sell
10,300
-5,300
-34% -$53.8K ﹤0.01% 10978
2023
Q2 		$165K Buy
15,600
+11,400
+271% +$135K ﹤0.01% 10186
2023
Q1 		$51.4K Sell
4,200
-2,400
-36% -$29.9K ﹤0.01% 12107
2022
Q4 		$81.9K Sell
6,600
-63,500
-91% -$923K ﹤0.01% 11496
2022
Q3 		$958K Buy
70,100
+900
+1% +$13.9K ﹤0.01% 7084
2022
Q2 		$1.27M Buy
69,200
+7,300
+12% +$105K ﹤0.01% 6483
2022
Q1 		$995K Buy
61,900
+13,300
+27% +$192K ﹤0.01% 7701
2021
Q4 		$680K Buy
48,600
+18,500
+61% +$300K ﹤0.01% 8909
2021
Q3 		$564K Buy
30,100
+16,400
+120% +$309K ﹤0.01% 9580
2021
Q2 		$286K Sell
13,700
-3,500
-20% -$86.9K ﹤0.01% 11385
2021
Q1 		$486K Sell
17,200
-29,200
-63% -$924K ﹤0.01% 9738
2020
Q4 		$1.51M Buy
46,400
+29,100
+168% +$1.02M ﹤0.01% 5953
2020
Q3 		$530K Sell
17,300
-400
-2% -$8.83K ﹤0.01% 7193
2020
Q2 		$289K Buy
+17,700
New +$255K ﹤0.01% 7967

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Citadel Advisors's KURA Position: Q2 2026 in Review

Citadel Advisors reduced its Kura Oncology (KURA) stake by 11% in Q2 2026, selling an estimated $384K and leaving 328,105 shares worth $3.6M. The position accounts for ﹤0.01% of the portfolio, ranked #5320.

Citadel Advisors first reported a position in KURA in Q2 2018 and has held it in 32 quarters since. The position peaked at $100M in Q4 2020. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Citadel Advisors held 328,105 shares of Kura Oncology worth $3.6M as of Q2 2026.
  • Citadel Advisors sold 40,720 Kura Oncology shares in Q2 2026, an estimated $384K.
  • Kura Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5320 holding.
  • Citadel Advisors first reported a position in Kura Oncology in Q2 2018 and has held it in 32 quarters since.
  • Citadel Advisors's Kura Oncology position peaked at $100M in Q4 2020.
  • 221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.